Login / Signup

No change in small low-density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial.

Tsutomu Hirano
Published in: Journal of diabetes investigation (2023)
Keyphrases
  • phase iii
  • study protocol
  • phase ii
  • clinical trial
  • open label